M
Michael Berk
Researcher at University of Melbourne
Publications - 1422
Citations - 71020
Michael Berk is an academic researcher from University of Melbourne. The author has contributed to research in topics: Bipolar disorder & Medicine. The author has an hindex of 116, co-authored 1284 publications receiving 57743 citations. Previous affiliations of Michael Berk include Monash University & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
Lakshmi N. Yatham,Sidney H. Kennedy,Sagar V. Parikh,Ayal Schaffer,Serge Beaulieu,Martin Alda,Claire O'Donovan,Glenda MacQueen,Roger S. McIntyre,Verinder Sharma,Arun V. Ravindran,L. Trevor Young,Roumen Milev,David J. Bond,Benicio N. Frey,Benjamin I. Goldstein,Beny Lafer,Boris Birmaher,Kyooseob Ha,Willem A. Nolen,Michael Berk,Michael Berk +21 more
TL;DR: The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009, and this third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunctionWith the previous publications.
Journal ArticleDOI
Pathways underlying neuroprogression in bipolar disorder : focus on inflammation, oxidative stress and neurotrophic factors
Michael Berk,Flávio Kapczinski,Ana Cristina Andreazza,Ana Cristina Andreazza,Olivia M Dean,Olivia M Dean,Francesco Giorlando,Francesco Giorlando,Michael Maes,Murat Yücel,Clarissa Severino Gama,Seetal Dodd,Seetal Dodd,Brian Dean,Brian Dean,Pedro Vieira da Silva Magalhães,Pedro Vieira da Silva Magalhães,G. Paul Amminger,Patrick D. McGorry,Gin S Malhi +19 more
TL;DR: Emerging data shows that these biomarkers may differ between early and late stages of BD in parallel with stage-related structural and neurocognitive alterations, which facilitates identification of rational therapeutic targets, and the development of novel treatment classes.
Journal ArticleDOI
So depression is an inflammatory disease, but where does the inflammation come from?
Michael Berk,Lana J. Williams,Lana J. Williams,Felice N. Jacka,Felice N. Jacka,Adrienne O'Neil,Adrienne O'Neil,Julie A. Pasco,Julie A. Pasco,Steven Moylan,Nicholas B. Allen,Amanda L Stuart,Amie C. Hayley,Michelle L. Byrne,Michael Maes,Michael Maes +15 more
TL;DR: The identification of known sources of inflammation provides support for inflammation as a mediating pathway to both risk and neuroprogression in depression.
Journal ArticleDOI
A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.
TL;DR: It is concluded that aberrations in O&NS pathways are--together with the inflammatory processes--key components of depression, and the results suggest that depression belongs to the spectrum of (neuro)degenerative disorders.
Journal ArticleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
Lakshmi N. Yatham,Sidney H. Kennedy,Sagar V. Parikh,Ayal Schaffer,David J. Bond,Benicio N. Frey,Verinder Sharma,Benjamin I. Goldstein,Soham Rej,Serge Beaulieu,Martin Alda,Glenda MacQueen,Roumen Milev,Arun V. Ravindran,Claire O'Donovan,Diane McIntosh,Raymond W. Lam,Gustavo Vazquez,Flávio Kapczinski,Roger S. McIntyre,Jan Marie Kozicky,Shigenobu Kanba,Beny Lafer,Trisha Suppes,Joseph R. Calabrese,Eduard Vieta,Gin S Malhi,Robert M. Post,Michael Berk +28 more
TL;DR: These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments.